Advice
in the absence of a submission from the holder of the marketing authorisation:
acoramidis (Beyonttra®) is not recommended for use within NHSScotland.
Indication under review: treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice355KB (PDF)
Medicine details
- Medicine name:
- acoramidis (Beyonttra)
- SMC ID:
- SMC2986
- Indication:
Treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 October 2026